Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 13, 2023

Long-Term Overall Survival Benefits With Tebentafusp in Patients With Metastatic Uveal Melanoma

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
N. Engl. J. Med 2023 Oct 21;[EPub Ahead of Print], JC Hassel, S Piperno-Neumann, P Rutkowski, JF Baurain, M Schlaak, MO Butler, RJ Sullivan, R Dummer, JM Kirkwood, M Orloff, JJ Sacco, S Ochsenreither, AM Joshua, L Gastaud, B Curti, JM Piulats, AKS Salama, AN Shoushtari, L Demidov, M Milhem, B Chmielowski, KB Kim, RD Carvajal, O Hamid, L Collins, K Ranade, C Holland, C Pfeiffer, P Nathan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading